Back to discover
Disease

Borderline Personality Disorder

Late-stage therapeutic developmentEmerging research
MeSHBorderline Personality Disorder
2
Publications
18
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q2 2027.
  • 2 industry developments reported.
Upcoming Milestones
Clinical Milestones5View
Results expected 2
Recently completed 3
Industry & Market2View
Activity timeline7

Clinical trials

15 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
8
Late-stage
6
Completed
Late-stage studies

A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder

Phase 2/3 · Completed · Otsuka Pharmaceutical Development & Commercialization, Inc.

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change

Phase 4 · Completed · New York State Psychiatric Institute

A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

Phase 3 · Completed · Mood and Anxiety Research, Inc

Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence

Phase 3 · Withdrawn · Elizabeth Ralevski

Seroquel XR for the Management of Borderline Personality Disorder (BPD)

Phase 3 · Completed · University of Minnesota

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder

Phase 4 · Completed · New York State Psychiatric Institute
Recruiting

The Effects of MDMA (3,4-methylenedioxymethamphetamine) in Social Cognition in Borderline Personality Disorder

Phase 2 · Recruiting · Yale University

A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct in Patients With Borderline Personality Disorder

Phase 2 · Recruiting · The Alfred

A Multi-center, Patient-blinded and Investigator-blinded, Randomized, Parallel-group, Superiority Study to Compare the Efficacy of Four Sessions of Amygdala fMRI-BOLD Neurofeedback With Yoked Sham-control Neurofeedback in the Treatment of Dysregulated Affect in Borderline Personality Disorder

Phase 1/2 · Recruiting · Central Institute of Mental Health, Mannheim

A Pilot Trial of One Day Accelerated Intermittent Theta-burst Stimulation Plus D-cycloserine in Suicidal Patients With Borderline Personality Disorder (ONE-D BPD)

Phase 1/2 · Recruiting · Mclean Hospital
Recently completed

A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder

Phase 2/3 · Completed · Otsuka Pharmaceutical Development & Commercialization, Inc.

"The Effects of Oxytocin on Patients With Borderline Personality Disorder"

N/A · Completed · Prof. Dr. Markus Heinrichs

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change

Phase 4 · Completed · New York State Psychiatric Institute

A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

Phase 3 · Completed · Mood and Anxiety Research, Inc

Seroquel XR for the Management of Borderline Personality Disorder (BPD)

Phase 3 · Completed · University of Minnesota

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder

Phase 4 · Completed · New York State Psychiatric Institute

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20062023
Major themes6
  • Attention Deficit Disorder with Hyperactivity1
  • Bipolar Disorder1
  • Borderline Personality Disorder1
  • Emotional Regulation1
  • Major Depressive Disorder1
  • Suicide Prevention1
Leading journals2
  • Archives of general psychiatry1
  • Psychological medicine1
Leading researchers8
  • Anmella G1
  • Brown MZ1
  • Comtois KA1
  • de Bartolomeis A1
  • De Prisco M1
  • Fico G1
  • Fornaro M1
  • Gallop RJ1
Affiliations (unnormalised)6
  • Behavioral Research and Therapy Clinics1
  • Centre for Psychiatric Research and Education1
  • Early Psychosis: Interventions and Clinical-Detection (EPIC) Lab1
  • Hospìtal Clinic de Barcelona. c. Villarroel1
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)1
  • Institute of Neurosciences (UBNeuro)1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A personality disorder marked by a pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts. (DSM-IV)

Identifiers
MeSHBorderline Personality Disorder
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.